Cargando…

Correction to: Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial

Detalles Bibliográficos
Autores principales:	Hölig, Kristina, Schmidt, Helmuth, Hütter, Gero, Kramer, Michael, Teipel, Raphael, Heidrich, Katharina, Zimmer, Kristin, Heidenreich, Falk, Blechschmidt, Matthias, Torosian, Tigran, Ordemann, Rainer, Kroschinsky, Frank, Rücker-Braun, Elke, Gopsca, Laszlo, Wagner-Drouet, Eva Maria, Oelschlaegel, Uta, Schmidt, Alexander H., Bornhäuser, Martin, Ehninger, Gerhard, Schetelig, Johannes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732266/ https://www.ncbi.nlm.nih.gov/pubmed/34773089 http://dx.doi.org/10.1038/s41409-021-01523-3

Ejemplares similares

Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial
por: Hölig, Kristina, et al.
Publicado: (2020)

Pilot Study on Mass Spectrometry–Based Analysis of the Proteome of CD34(+)CD123(+) Progenitor Cells for the Identification of Potential Targets for Immunotherapy in Acute Myeloid Leukemia
por: Schmidt, Johannes R., et al.
Publicado: (2018)

Reevaluation of reference values for bone marrow differential counts in 236 healthy bone marrow donors
por: Parmentier, Stefani, et al.
Publicado: (2020)

Plerixafor
por: Slater, Susan
Publicado: (2012)

Clonal hematopoiesis and its emerging effects on cellular therapies
por: von Bonin, Malte, et al.
Publicado: (2021)

Plerixafor as a salvage mobilization strategy for haploidentical peripheral blood allogeneic stem cell transplantation
por: Nadeau, Michelle, et al.
Publicado: (2015)

Plerixafor as a preemptive or salvage therapy for healthy donors with poor mobilization of hematopoietic stem cells
por: Kuang, Pu, et al.
Publicado: (2022)

Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse
por: Sockel, Katja, et al.
Publicado: (2022)

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
por: Platzbecker, U, et al.
Publicado: (2012)

Klonale Hämatopoese – Bedeutung für die Zelltherapie
por: Teipel, Raphael, et al.
Publicado: (2022)

Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization
por: Awan, Farrukh T., et al.
Publicado: (2012)

Clonal architecture of del(5q) myelodysplastic syndromes: aberrant CD5 or CD7 expression within the myeloid progenitor compartment defines a subset with high clonal burden
por: Oelschlaegel, U, et al.
Publicado: (2016)

Plerixafor for autologous CD34(+) cell mobilization
por: Salman, Huda, et al.
Publicado: (2011)

Efficacy of Afternoon Plerixafor Administration for Stem Cell Mobilization
por: El Rahi, Cynthia, et al.
Publicado: (2018)

Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment
por: Teipel, Raphael, et al.
Publicado: (2022)

An optimized targeted Next-Generation Sequencing approach for sensitive detection of single nucleotide variants
por: Stasik, S., et al.
Publicado: (2018)

T-cell receptor-α repertoire of CD8+ T cells following allogeneic stem cell transplantation using next-generation sequencing
por: Link-Rachner, Cornelia S., et al.
Publicado: (2019)

Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03)
por: van de Wyngaert, Zoe, et al.
Publicado: (2023)

Plerixafor use for peripheral blood stem cell mobilization in Korea
por: Kim, Seok Jin, et al.
Publicado: (2013)

Addition of plerixafor in poorly mobilized allogeneic stem cell donors
por: Zhuang, Lefan, et al.
Publicado: (2022)

Case Study in Refractory Non-Hodgkin's Lymphoma: Successful Treatment with Plerixafor
por: Azim, Hamdy Abdel, et al.
Publicado: (2011)

Plerixafor in the Treatment of Stem Cell Mobilization Failure; First Experience in Iran
por: Mehdizadeh, Mahshid, et al.
Publicado: (2013)

Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor
por: Fadini, Gian Paolo, et al.
Publicado: (2015)

Use of Plerixafor to Mobilize a Healthy Donor Infected with Influenza A
por: Yeral, Mahmut, et al.
Publicado: (2018)

P2 3-year observation study of Plerixafor use in New Zealand
por: Swinn, Tim, et al.
Publicado: (2021)

Plerixafor stem cell mobilization in Japanese children: A post‐marketing study
por: Goto, Hiroaki, et al.
Publicado: (2022)

Development and validation of a predictive model to guide the use of plerixafor in pediatric population
por: Sebastien, Bernard, et al.
Publicado: (2022)

Plerixafor in non-Hodgkin’s lymphoma patients: a German analysis of time, effort and costs
por: Hübel, Kai, et al.
Publicado: (2018)

P1343: TRANSPLANT OUTCOMES OF LYMPHOMA PATIENTS UNDERGOING STEM CELL MOBILIZATION WITH PLERIXAFOR
por: Gunes, A. K., et al.
Publicado: (2022)

Prevalence of human herpesvirus 6 antibodies and DNA in allogeneic stem cell transplant patients: two-year single centre experience
por: Dzieciątkowski, Tomasz, et al.
Publicado: (2008)

Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury
por: Heuschkel, Sandra, et al.
Publicado: (2021)

Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update
por: Bilgin, Yavuz M
Publicado: (2021)

Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears
por: Eckardt, Jan-Niklas, et al.
Publicado: (2021)

Deep sequencing in CD34(+) cells from peripheral blood enables sensitive detection of measurable residual disease in AML
por: Stasik, Sebastian, et al.
Publicado: (2022)

Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase
por: Alakel, Nael, et al.
Publicado: (2017)

Individual HLA-A, -B, -C, and -DRB1 Genotypes Are No Major Factors Which Determine COVID-19 Severity
por: Schetelig, Johannes, et al.
Publicado: (2021)

Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia
por: Roboz, Gail J., et al.
Publicado: (2018)

Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration
por: De Clercq, Erik
Publicado: (2019)

Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor
por: Uchida, Naoya, et al.
Publicado: (2020)

Hematopoietic Stem Cell Mobilization With Plerixafor Is Safe and Effective in Poorly Mobilizing Acute Myeloid Leukemia Patients
por: Shumilov, Evgenyi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_f3vk2rv2a7f9clrglhm22hd2gb